

Current report no. 21/2020
July 13, 2020

Shareholders controlling at least 5% of the vote at the General Meeting of Ryvu Therapeutics S.A. convened on July, 13 2020

The Management Board of Ryvu Therapeutics S.A. with its registered office in Cracow ("Company") hereby announces that the following shareholders controlled at least 5% of the vote at the General Meeting of the Company ("General Meeting") convened on July, 13 2020:

1. Paweł Przewięźlikowski, who held 4.990.880 shares of the Company and controlled 8.490.880 votes, which corresponds to 44,39% of the shares represented at the General Meeting, 55,52% of the votes represented at the General Meeting and 42,41% of the total number of votes;
2. Nationale-Nederlanden Otwarty Fundusz Emerytalny, which held 1.594.749 shares of the Company and controlled 1.594.749 votes, which corresponds to 14,18% of the shares represented at the General Meeting, 10,43% of the votes represented at the General Meeting and 7,97% of the total number of votes;
3. Bogusław Sieczkowski, who held 800.000 shares of the Company and controlled 1.350.000 votes, which corresponds to 7,11% of the shares represented at the General Meeting, 8,83% of the votes represented at the General Meeting and 6,74% of the total number of votes;
4. Augebit FIZ, which held 1.039.738 shares of the Company and controlled 1.039.738 votes, which corresponds to 9,25% of the shares represented at the General Meeting, 6,8% of the votes represented at the General Meeting and 5,19% of the total number of votes;
5. OFE Aviva Santander, which held 774.433 shares of the Company and controlled 774.433 votes, which corresponds to 6,89% of the shares represented at the General Meeting, 5,06% of the votes represented at the General Meeting and 4,85% of the total number of votes.

According to the list of attendance at the General Meeting of the Company, 11.244.040 shares of the Company (giving the right to 15.294.040 votes) were represented at the General Meeting.

The total number of shares in the Company is 15.971.229 and gives the right to 20.021.229 votes.

Legal basis: art. 70.3 of the Act on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organised Trading and Public Companies, dated 29 July 2005

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board